Prior Events Predict Cerebrovascular and Coronary Outcomes in the Progress Trial.
From: The George Institute for International Health, University of Sydney, Australia.
Stroke; a journal of cerebral circulation
- Publish Date: Jun 2006
- ISSN: 1524-4628
- Volume: 37
- Issue: 6
- Pages: 1497-502
- Medium: Internet
- Language: English
- Citation (JAMA): Arima Hisatomi, Tzourio Christophe, Butcher Ken, et al. Prior Events Predict Cerebrovascular and Coronary Outcomes in the Progress Trial.. Stroke Jun 2006;37:1497-502
Abstract
BACKGROUND AND PURPOSE: The relationship between baseline and recurrent vascular events may be important in the targeting of secondary prevention strategies. We examined the relationship between initial event and various types of further vascular outcomes and associated effects of blood pressure (BP)-lowering. METHODS: Subsidiary analyses of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a randomized, placebo-controlled trial that established the benefits of BP-lowering in 6105 patients (mean age 64 years, 30% female) with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, plus indapamide in those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). RESULTS: Stroke subtypes and coronary events were associated with 1.5- to 6.6-fold greater risk of recurrence of the same event (hazard ratios, 1.51 to 6.64; P=0.1 for large artery infarction, P<0.0001 for other events). However, 46% to 92% of further vascular outcomes were not of the same type. Active treatment produced comparable reductions in the risk of vascular outcomes among patients with a broad range of vascular events at entry (relative risk reduction, 25%; P<0.0001 for ischemic stroke; 42%, P=0.0006 for hemorrhagic stroke; 17%, P=0.3 for coronary events; P homogeneity=0.4). CONCLUSIONS: Patients with previous vascular events are at high risk of recurrences of the same event. However, because they are also at risk of other vascular outcomes, a broad range of secondary prevention strategies is necessary for their treatment. BP-lowering is likely to be one of the most effective and generalizable strategies across a variety of major vascular events including stroke and myocardial infarction.
Mesh Headings (Keywords): Aged, Antihypertensive Agents, Blood Pressure, Brain Ischemia, Cerebral Hemorrhage, Coronary Disease, Female, Humans, Male, Middle Aged, Perindopril, Randomized Controlled Trials as Topic, Recurrence, Risk Factors, Risk Reduction Behavior, Stroke, Vascular Diseases
Check for Full Text / PubMed Unique Identifier (PMID): 16627794
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.